Financial Data and Key Metrics Changes - Revenue for Q3 2025 increased by 21% to $200.2 million compared to $166 million in Q3 2024, driven by growth in storage and utility segments [21][31] - Gross margin improved to $12.9 million or 6.4% in Q3 2025 from $5.6 million or 3.4% in Q3 2024 [21][22] - The company reported a net loss of $3.4 million or $0.12 per share, an improvement from a net loss of $14.6 million or $0.53 per share in the same quarter last year [23] Business Line Data and Key Metrics Changes - Storage and Thermal Solutions segment revenue surged by 77% to $96.1 million in Q3 2025 from $54.3 million in Q3 2024, driven by specialty vessel projects [23][24] - Utility and Power Infrastructure segment revenue rose by 27% to $58.7 million compared to $46.1 million in the prior year, benefiting from natural gas peak shaving projects [25] - Process and Industrial Facilities segment revenue decreased to $45.4 million from $65.6 million, primarily due to the completion of a large renewable diesel project [26] Market Data and Key Metrics Changes - The company anticipates a 45% increase in U.S. LNG export demand, supporting elevated energy infrastructure spending [16] - The EIA projects an 8% increase in natural gas demand over the next six years, indicating strong growth potential in the electrical infrastructure market [17] Company Strategy and Development Direction - The company is restructuring to create a more efficient organization, including eliminating senior positions and decentralizing business development [8][11] - Matrix is winding down its Northeast transmission and distribution service line due to competitive disadvantages, while continuing to focus on electrical infrastructure services [12][13] - The strategic focus remains on delivering sustainable long-term shareholder value through a resilient growth-oriented platform [13] Management's Comments on Operating Environment and Future Outlook - Management noted macroeconomic uncertainties due to U.S. trade and environmental policies, but believes the underlying demand environment remains strong [14] - The company revised its fiscal 2025 revenue guidance down by 10% to $770 million to $800 million, while still expecting strong year-over-year growth [15][31] - Management expressed confidence in achieving a sustainable and profitable growth trajectory, supported by a $7 billion pipeline of project opportunities [17] Other Important Information - The company reported a backlog increase of nearly 8% sequentially to over $1.4 billion, with a book-to-bill ratio of 1.5 [18] - Cash flow from operating activities was $31.2 million for Q3 and $76.8 million year-to-date, with available liquidity increasing to $247.1 million [30] Q&A Session Summary Question: Can you walk us through the decision-making process to exit the transmission and distribution business? - Management indicated that competitive dynamics made it difficult to win work at acceptable margins, leading to the decision to wind down the business without a positive backlog [35][36] Question: What are the potential cost savings from exiting the business? - The exit will result in cost savings and reallocation of resources to the electrical instrumentation business, with the business operating at a loss previously [38] Question: Are the revenue guidance adjustments due to deferrals or cancellations? - Management clarified that some revenue was deferred due to delays in contract negotiations and project awards, but they expect strong spending on energy infrastructure in the coming years [39][42] Question: What is the opportunity profile for smaller projects as the company reengages in them? - Management emphasized the importance of smaller projects for building client relationships and strengthening execution teams, indicating a need to pursue these opportunities more effectively [43][44] Question: How might the geopolitical macroeconomic environment influence customer spending? - Management expressed confidence that despite uncertainties, the global demand for energy will continue to rise, supporting infrastructure investments [51][53]

Financial Data and Key Metrics Changes - The company achieved record total net revenue of $52.6 million for the first quarter, with MACI revenue of $46.3 million, Epicel revenue of $5 million, and NexoBrid revenue of $1.3 million [13] - MACI revenue grew by 15% year-over-year, which adjusts to approximately 17% growth when accounting for one fewer selling day in the quarter [14] - NexoBrid revenue increased by 207% year-over-year and 31% sequentially [14] - The net loss for the quarter was $11.2 million, or $0.23 per share, with non-GAAP adjusted EBITDA of $3.2 million, representing 6% of net revenue [16] Business Line Data and Key Metrics Changes - MACI had a strong quarter with record revenue exceeding $46 million, driven by strong underlying fundamentals and a growing surgeon customer base [6][5] - NexoBrid's revenue growth was significant, with over 200% increase compared to the previous year, indicating strong market penetration [10] - Epicel revenue was lower than anticipated due to a high percentage of canceled cases, but there was a strong start to the second quarter with graft volumes exceeding the first quarter [11][12] Market Data and Key Metrics Changes - The company expects total revenue growth of 22% to 25% for the second quarter, with MACI revenue projected to be approximately $54 million [18] - The addressable market for MACI is estimated at 60,000 patients annually, with significant opportunities in femoral condyle and trochlear defects [26][20] Company Strategy and Development Direction - The company is advancing the MACI Ankle Development Program and plans to initiate a Phase III clinical study in the second half of the year, which represents a substantial long-term growth driver [20] - The company plans to expand its MACI sales force in the second half of the year to support growth driven by MACI Arthro [10][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about strong second quarter performance based on positive trends observed in the first quarter, reaffirming full-year revenue guidance of 20% to 23% growth [5][17] - The company anticipates minimal impact from tariffs due to its domestic manufacturing and significant safety stock of materials [17] Other Important Information - The company generated $6.6 million in operating cash flow and ended the quarter with approximately $162 million in cash and no debt [16] - Management raised profitability guidance for the year, expecting gross margins to reach 75% and adjusted EBITDA margins to reach 26% [18] Q&A Session Summary Question: Can you discuss the market opportunity for femoral condyle and trochlear specifically? - Management indicated that the MACI Arthro instruments are designed for femoral condyle defects, which represent a significant portion of the addressable market, and there is potential for treating trochlear defects as well [26][27] Question: How do you see seasonality and pacing for MACI in the second half of the year? - Management noted that while MACI typically follows a prescriptive pattern, strong leading indicators suggest potential for stronger growth in the second half of the year [32][33] Question: What is the contribution of MACI Arthro to first quarter numbers? - Management acknowledged that while there was some incremental impact from MACI Arthro, the full effect is expected to be seen in the second half of the year [38][40] Question: How have recent trade war headlines impacted international views on MACI? - Management stated that they are evaluating potential for MACI outside the U.S. but will consider tariffs and trade impacts before making decisions [92] Question: Can you provide insights on conversion rates for MACI Arthro procedures? - Management indicated that it is early to assess conversion rates, but they expect higher rates over time due to the less invasive nature of the procedure [57][66] Question: What are the dynamics of cross-selling opportunities between Epicel and NexoBrid? - Management confirmed that they are seeing biopsies from previously dormant accounts and expect this trend to continue as they cross-sell products [61] Question: Can you elaborate on the sales force expansion plans? - Management indicated that while the expansion is not full-scale this year, they are preparing to add resources to support expected growth [80][81]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $36.3 million, down 26% year over year and down 18% in constant currency, primarily due to lower corporate sales in Egypt and currency devaluation [19][36]. - Adjusted EBITDA loss was $15.7 million in Q1 2025, compared to a loss of $4.3 million in Q1 2024 [19][41]. - Loss before income tax was $16.5 million, a significant improvement from $39.6 million in the same period last year [19][41]. Business Line Data and Key Metrics Changes - Marketplace revenue for Q1 was $18.1 million, down 30% year over year [36]. - Revenue from first-party sales was $17.8 million, down 21% year over year [36]. - Fulfillment expense per order decreased to $2.07, down 14% year over year, indicating improved efficiency [39][11]. Market Data and Key Metrics Changes - GMV declined 11% year over year, primarily due to currency headwinds and lower corporate sales, particularly in Egypt [16][19]. - Excluding corporate sales, GMV would have grown 10% year over year, highlighting strengths in the consumer business [16][19]. - Physical Goods orders grew 21% year over year, driven by strong demand [15][19]. Company Strategy and Development Direction - The company aims to reduce losses, drive efficiency, and deliver measurable financial improvements, with a focus on margin expansion and financial discipline [6][7]. - Jumia is expanding its logistics network to monetize its infrastructure beyond the core marketplace, which is expected to enhance cost efficiency [28][62]. - The company is targeting profitability by 2027, with a loss before income tax forecasted to improve significantly in 2026 [9][45]. Management's Comments on Operating Environment and Future Outlook - Management noted that while currency headwinds have impacted profitability, they expect to see improved growth trends moving forward as these effects have lapped [18][32]. - The company remains confident in its strategy and believes it is well-positioned to capture supply from Asia as global trade dynamics shift [32][56]. - Management emphasized the importance of operational discipline and cost management in achieving sustainable growth [43][33]. Other Important Information - The company has reduced its total headcount by about 3% as part of its cost control measures [11]. - Jumia's liquidity position at the end of Q1 was $110.7 million, including cash and cash equivalents [42]. - The company remains debt-free, with borrowing related solely to lease liabilities [43]. Q&A Session Summary Question: Can you explain the relationship between orders and GMV? - Corporate sales are typically high-value orders that generate significant GMV with few orders, leading to a disconnect when corporate sales decrease [49]. Question: How should we think about cash use from inventory levels? - A significant part of cash burn is due to increased working capital for inventory ahead of major campaigns, but lower impacts are expected in the coming quarters [54]. Question: Have you seen an uptick in supply from Asia? - There has been a strong trend in item sales from international vendors, particularly from China, with a 61% increase in gross items sold [55]. Question: What is the monetization strategy for the Jumia delivery business? - The delivery business is designed to be higher margin and lower volume compared to marketplace revenue, with profitability from day one [90]. Question: How significant is the deliveries business to revenue for Ivory Coast? - The deliveries business is profitable but lower than marketplace revenues, with potential for further scaling [93].

Financial Data and Key Metrics Changes - The company achieved record total net revenue of $52.6 million for Q1 2025, with MACI revenue of $46.3 million, Epicel revenue of $5 million, and NexoBrid revenue of $1.3 million [12] - MACI revenue grew by 15% year-over-year, which adjusts to approximately 17% growth when accounting for one fewer selling day in the quarter [12] - NexoBrid revenue increased by 207% year-over-year and 31% sequentially [12] - The net loss for the quarter was $11.2 million, or $0.23 per share, with non-GAAP adjusted EBITDA of $3.2 million, representing 6% of net revenue [15] Business Line Data and Key Metrics Changes - MACI had a strong quarter with record revenue exceeding $46 million, driven by strong underlying fundamentals and a growing surgeon customer base [6] - NexoBrid revenue showed significant growth, indicating progress in its launch and deeper penetration in ordering centers [10] - Epicel revenue was lower than anticipated due to a high percentage of canceled cases related to patient health issues, despite the highest number of biopsies since 2023 [10][13] Market Data and Key Metrics Changes - The company expects total revenue growth of 22% to 25% for Q2 2025, with MACI revenue projected to be approximately $54 million [17] - The addressable market for MACI is estimated at 60,000 patients annually, with significant opportunities in treating femoral condyle and trochlear defects [24][25] Company Strategy and Development Direction - The company plans to expand its MACI sales force in the second half of 2025, driven by strong early indicators from the MACI Arthro launch [9][19] - The MACI Ankle Development Program is on track to initiate Phase III clinical studies, representing a substantial long-term growth driver with an estimated market of $1 billion [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about strong underlying MACI business fundamentals and early indicators from the MACI Arthro launch, suggesting potential for incremental growth [20] - The company reaffirmed its full-year revenue guidance of 20% to 23% growth and raised profitability guidance, expecting gross margins to reach 75% and adjusted EBITDA margins to 26% for the year [17] Other Important Information - The company ended the quarter with approximately $162 million in cash, restricted cash, and investments, with no debt [15] - Management noted that tariffs are expected to have a negligible impact on the business due to domestic manufacturing and significant safety stock [16] Q&A Session Summary Question: Can you discuss the market opportunity for femoral condyle and trochlear specifically? - Management indicated that the MACI Arthro instruments are designed for femoral condyle defects, representing a significant portion of the addressable market, and surgeons are also using them for trochlear defects, expanding the potential market [24][25] Question: How do you see seasonality and pacing for MACI in the second half of the year? - Management acknowledged that while MACI typically follows a seasonal pattern, strong leading indicators suggest potential for enhanced growth in the second half of the year [30][31] Question: What is the contribution of MACI Arthro to the first quarter numbers? - Management noted that while it is difficult to quantify the exact contribution from MACI Arthro in Q1, they expect a more significant impact in the second half of the year [36][37] Question: How are you prioritizing MACI Arthro training among surgeon groups? - Management explained that training occurs through industry events and individual sessions, focusing first on existing MACI users before targeting new surgeons [92][93] Question: How has the recent trade war impacted your view on MACI internationally? - Management stated that they are evaluating the potential for MACI outside the U.S. and will consider trade impacts before making decisions [90][91]

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [29][30] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million [16][30] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [8][30] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [12][36] - Other products, including Zejula and NUZYRA, delivered sequential growth supported by NRDL access, with early contributions from OGTYRO and ZACDURO [15] - The company is preparing for upcoming NRDL cycles targeting IV renewal for gMG and initial listing of the SC formulation [14] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [63] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [63] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on differentiated and high-potential assets, including GL1310 and other novel therapies [9][10] - Investments are being made to accelerate the global R&D pipeline, with plans to present updated Phase I data at ASCO [10][20] - The company is committed to achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage opportunity pipeline [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue targets and surpassing $2 billion by 2028, with strong momentum expected to carry into the 2030s [9] - The management team highlighted the importance of strategic initiatives to extend treatment duration and improve patient access [12][14] - The company remains optimistic about its financial position, ending Q1 with a cash position of $857.3 million [31] Other Important Information - The company is advancing its internal pipeline while also considering external opportunities for in-licensing [102][103] - Regulatory discussions with the FDA are ongoing, with no significant changes noted in the approval process despite recent leadership changes at the FDA [53][105] Q&A Session Summary Question: Can you provide more color on VIBGART's sequential change? - Management indicated that the sequential decline was influenced by seasonality and inventory dynamics, with confidence in recovery based on strong patient volumes in April [33][36] Question: Are you comfortable with consensus estimates for VIBGART and fiscal year revenues? - Management reaffirmed their revenue guidance and expressed confidence that VIBGART sales would grow faster than overall business rates [42][44] Question: How do recent FDA changes impact Zai Lab? - Management noted no anticipated impact from tariffs and indicated that FDA interactions have remained productive [50][53] Question: What is the competitive landscape for gMG in China? - Management believes that new approvals will benefit the market and enhance treatment options for patients [63] Question: What is the strategy regarding in-house developed assets? - The company plans to maintain a balanced approach between in-house development and external licensing opportunities [102][103]

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [27] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million, reflecting operational efficiency [15][27] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [6][28] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [11][12] - Other products, including Zejula and NUZYRA, showed sequential growth supported by NRDL access, with early contributions from newly launched products like OGTYRO and ZACDURO [14] - The company is preparing for the upcoming NRDL cycle targeting IV renewal for gMG and initial listing of the SC formulation, effective January 1, 2026 [12] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [60] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [60] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on innovative therapies and maintaining a balanced approach between in-house development and business development opportunities [8][100] - Investments are being made to accelerate the global R&D pipeline, with a commitment to advancing at least one global product to IND submission stage every year [23] - The company is focused on achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage pipeline [15][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability by Q4 2025, citing strong business fundamentals and strategic direction [6][27] - The company anticipates accelerating sales growth in the next three quarters, which will translate into significant operating leverage [6] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [15][28] Other Important Information - The company ended the quarter with a strong cash position of $857.3 million, providing a solid foundation for future investments and growth initiatives [29] - The company is actively pursuing regulatory reviews for multiple products, including CAR XT for schizophrenia and TIVDAC for cervical cancer [15] Q&A Session Summary Question: Can you describe the sequential change in VIBGART sales? - Management indicated that the sequential decline was influenced by seasonal trends and inventory dynamics, with a strong recovery in patient volumes observed in March and April [31][32] Question: Are you comfortable with the current consensus for VIBGART and fiscal year revenues? - Management reaffirmed confidence in the revenue guidance range of $560 million to $590 million, indicating that VIBGART sales are expected to grow faster than overall sales growth [41] Question: How do recent FDA changes and tariffs impact Zai Lab? - Management noted no anticipated impact from tariffs, as local manufacturing is in place for many products, and FDA interactions have remained productive [46][50] Question: What is the competitive landscape for gMG in China? - Management expressed optimism about the competitive dynamics, stating that new approvals will benefit the overall market and enhance treatment options for patients [60] Question: What is the strategy regarding in-house developed assets versus in-licensing? - Management indicated a balanced approach, continuing to pursue both in-house development and high-quality external opportunities [100]

Financial Performance & Targets - Zai Lab reported a 22% year-over-year increase in total revenues for 1Q'25, reaching $106.5 million[8][44] - The company is targeting profitability in 4Q'25[13][41][48][53][54][75] - Zai Lab anticipates total revenue between $560 million and $590 million[41] - As of March 31, 2025, Zai Lab's cash position was strong at $857.3 million, compared to $879.7 million as of December 31, 2024[9][10][42][76] Key Product Performance & Pipeline Updates - VYVGART/VYVGART Hytrulo sales increased by 38% year-over-year in 1Q'25, reaching $18.1 million[44] - NUZYRA sales increased by 53% year-over-year in 1Q'25, reaching $15.1 million[44] - ZEJULA maintained its position as the leading PARP inhibitor in hospital sales for ovarian cancer[47] - Two NDAs, KarXT for schizophrenia and TIVDAK for cervical cancer, are under NMPA review[7] - ZL-1310 (DLL3 ADC) is progressing rapidly, with updated data to be presented at ASCO and a pivotal trial to be initiated in 2H'25[7][35][56][70] Strategic Focus & Pipeline Expansion - The company aims to generate at least 1-2 INDs per year[40] - Zai Lab is expanding its immunology franchise with Povetacicept (APRIL/BAFF) and VRDN-003 (IGF-1R)[7] - The company is preparing for potential launches of KarXT and bemarituzumab[19][67][72] - Zai Lab is planning local manufacturing for key products like KarXT and bemarituzumab[19][28]

Financial Data and Key Metrics Changes - Revenue for the first quarter was $29.8 million, reflecting a 6% growth from the first quarter of the previous year [6][21] - Recurring revenue grew 20% year-over-year to $22.7 million [7][22] - Non-GAAP gross margin was 37.6%, an increase of 650 basis points from 31.1% in the prior year [9][22] - Non-GAAP operating loss was $13.4 million, 40% lower than the previous year, marking the lowest level since the company went public [24] Business Line Data and Key Metrics Changes - Console revenue grew 23% sequentially, reaching $7.1 million [21] - Consumable revenue was $14.2 million, contributing to a total product revenue of $21.3 million, which grew 4% from the prior year [21] - Service and other revenue increased by 9% to $8.5 million [22] Market Data and Key Metrics Changes - The company saw strong utilization across the Tableau installed base, contributing to recurring revenue growth [7][10] - The installed base performed over 1 million treatments annually, with significant potential for additional recurring revenue [17] Company Strategy and Development Direction - The company is focused on three priorities for 2025: growing console revenue, increasing gross margin, and driving towards profitability [18][19] - The strategy includes expanding the installed base and leveraging operational efficiencies to achieve a gross margin milestone of 50% [19][25] - The company is optimistic about its competitive advantages in both acute and home settings, emphasizing the clinical and financial benefits of insourcing with Tableau [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline and market demand, noting that insourcing with Tableau remains compelling for healthcare providers [12][20] - The company is closely monitoring the economic environment but has not observed any negative impacts on hospital capital spending to date [48][50] - Management remains conservative in guidance, expecting revenue growth to build throughout the year [68] Other Important Information - The company successfully completed a recapitalization and is focused on aligning employee interests with those of investors [14] - The company has received tariff exemptions for its medical devices, ensuring no impact from proposed tariffs [15] Q&A Session Summary Question: Details on the turnaround in the console selling process - Management noted significant progress in the sales transformation and strong customer demand, with expectations that the transformation will be complete in the first half of 2025 [30][34] Question: Risk of macro headwinds affecting hospitals - Management indicated that there have been no observed changes in hospital capital spending and emphasized the tangible savings Tableau provides [48][50] Question: Guidance adjustments and business momentum - Management chose not to adjust guidance despite a strong quarter, maintaining a conservative approach while expecting sequential revenue growth [64][68] Question: Console installed base growth - Management confirmed console revenue increased by 23% from the previous quarter, with strong performance in treatments [74]

Core Insights - Matrix Service Company reported strong revenue growth in the third quarter of fiscal 2025, driven by increased activity in its Storage & Terminal Solutions and Utility & Power Infrastructure segments, achieving a revenue of $200.2 million, up 21% from $166.0 million in the same quarter of the previous year [5][9] - The company experienced a book-to-bill ratio of 1.5x for the quarter, indicating strong demand in core energy and industrial markets, with total project awards of $301.2 million [7][13] - Despite a reduction in fiscal year revenue guidance by 10% due to macroeconomic uncertainties, the company maintains a robust backlog of $1.4 billion and a project pipeline valued at $7 billion, suggesting continued growth potential [3][4][18] Financial Summary - Revenue for the third quarter of fiscal 2025 was $200.2 million, a 21% increase from $166.0 million in the prior year [5] - Gross margin improved to $12.9 million (6.4%) compared to $5.6 million (3.4%) in the same quarter of fiscal 2024, attributed to better performance in Utility and Power Infrastructure and Process and Industrial Facilities segments [6] - The company reported a net loss of $(3.4) million or $(0.12) per share, an improvement from a net loss of $(14.6) million or $(0.53) per share in the prior year [9] Segment Performance - The Storage and Terminal Solutions segment saw revenue increase by 77% to $96.1 million, driven by higher volumes in specialty vessel and LNG storage projects, although gross margin slightly decreased to 3.9% [10] - The Utility and Power Infrastructure segment's revenue rose 27% to $58.7 million, with gross margin improving significantly to 9.4% due to effective project execution [11] - The Process and Industrial Facilities segment experienced a revenue decline to $45.4 million, primarily due to the completion of a large renewable diesel project, but gross margin improved to 8.3% [12] Backlog and Project Awards - The total backlog increased by 7.7% to $1.4 billion as of March 31, 2025, with project awards totaling $301.2 million for the quarter [7][13] - The book-to-bill ratio for the quarter was 1.5x, with significant contributions from the Storage and Terminal Solutions segment, which had a book-to-bill ratio of 2.1x [13][42] Financial Position - As of March 31, 2025, the company had total liquidity of $247.1 million, consisting of $185.5 million in unrestricted cash and cash equivalents, with no outstanding debt [16] - Cash flow from operations for the quarter was $31.2 million, reflecting strong scheduled payments from customers [14] Fiscal Year 2025 Guidance - The company updated its fiscal year 2025 revenue guidance to a range of $770 million to $800 million, down from the previous guidance of $850 million to $900 million, due to external uncertainties affecting project timelines [18]

Financial Data and Key Metrics Changes - The company reported revenue of $1.2 billion in Q1 2025, roughly in line with the same quarter in 2024, with 2,946 homes sold [18] - Acquisition volumes increased by 4% year-over-year, with 3,609 homes purchased in Q1 2025 [18] - Contribution profit was $54 million in Q1 2025, down from $57 million in Q1 2024, resulting in a contribution margin of 4.7% [19] - Adjusted EBITDA loss improved to $30 million in Q1 2025 from a loss of $50 million in Q1 2024, driven by reduced operating expenses [19] - Fixed operating expenses decreased by $19 million, or 33%, compared to the previous year [15] Business Line Data and Key Metrics Changes - The company is focusing on enhancing its product flow and pricing models to improve conversion rates despite higher spreads [19] - The strategy includes maintaining pricing discipline and improving conversion through better pricing models and marketing investments [12][13] Market Data and Key Metrics Changes - The housing market is experiencing challenges, with mortgage rates exceeding 7%, clearance rates down nearly 25% year-over-year, and delistings up over 30% [6][7] - The company anticipates continued headwinds in the housing market, impacting performance in the near term [21] Company Strategy and Development Direction - The company aims to drive towards profitability while enhancing product experience and leadership position in the residential real estate market [8] - A new strategy involves expanding partnerships with agents to provide customers with more selling options, including cash offers and traditional listings [9][10] - The company is piloting a new experience in select markets to improve conversion rates and customer satisfaction [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging macroeconomic environment and the need for a cautious approach due to consumer hesitation [24] - The outlook for Q2 2025 includes expected revenue between $1.45 billion and $1.525 billion, with a contribution profit of $65 million to $75 million [21] - The company expects to see a decline in revenue year-over-year in the latter half of the year due to a slowdown in acquisitions [24] Other Important Information - The company ended the quarter with 7,080 homes in inventory, valued at $2.4 billion, a 24% increase from the prior year [20] - Total capital at quarter-end was $1 billion, primarily consisting of $559 million in unrestricted cash [20] Q&A Session Summary Question: Acquisition growth slowdown and market performance - Management expects a seasonal pattern in acquisitions, with a decline from Q1 to Q2 and a ramp-up in Q4, indicating a cautious approach due to market uncertainty [29] Question: Health of older inventory and valuation - Management noted that older inventory typically has lower margins, but recent acquisitions are performing well, providing confidence in future contribution margins [36] Question: Agent partnership expansion - The company is shifting to a model where agents are brought in earlier in the process, enhancing conversion and providing local expertise [42] Question: Cost savings opportunities - Management highlighted ongoing efforts to optimize the cost structure, with a significant reduction in fixed costs already achieved [53] Question: Marketing expense reduction - The majority of the expected reduction in operating expenses is attributed to lower marketing spend due to seasonal dynamics [58] Question: Economics of the agent partnership - The partnership will generate revenue through commission sharing on listings and margins on cash offers, with expectations that conversion benefits will outweigh referral costs [61]